AI assistant
Sending…
CRESCENT BIOPHARMA, INC. — Director's Dealing 2018
May 24, 2018
33678_dirs_2018-05-24_bfcd929e-81b3-4fde-868e-c64f73141c33.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: GLYCOMIMETICS INC (GLYC)
CIK: 0001253689
Period of Report: 2018-05-23
Reporting Person: Magnani John L. (Director, SVP of Research, CSO)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2018-05-23 | Common Stock | M | 1491 | $0.33 | Acquired | 100793 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2018-05-23 | Warrant to Purchase Common Stock (right to buy) | $0.33 | M | 895 | Disposed | 2018-07-03 | Common Stock (895) | Direct |
| 2018-05-23 | Warrant to Purchase Common Stock (right to buy) | $0.33 | M | 596 | Disposed | 2019-01-16 | Common Stock (596) | Direct |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 4845 | Indirect |
Footnotes
F1: These shares are held by GlycoTech Corporation, of which the reporting person is the sole stockholder.
More from CRESCENT BIOPHARMA, INC.
Declaration of Voting Results & Voting Rights Announcements
2026
Jun 3
Earnings Release
2026
Feb 26
Annual Report
2026
Feb 26
Major Shareholding Notification
2026
Feb 5
Capital/Financing Update
2026
Jan 15
Capital/Financing Update
2026
Jan 7
Director's Dealing
2025
Dec 17
Director's Dealing
2025
Dec 17
Director's Dealing
2025
Dec 17
Director's Dealing
2025
Dec 17